Victor Valcour
University Of California San Francisco
Project start date: 2010-05-18
Project end date: 2015-01-31
Sponsored Links Excellgen http://Excellgen.com
Grants awarded to Victor Valcour
NEURODEVELOPMENT AND IMAGING AMONG HIV-INFECTED CHILDREN FROM THE PREDICT STUDY
Victor Valcour, Assistant Professor
University Of California San Francisco, 3333 California St., Ste 315, San Francisco, Ca 94143-0962
Grant 1R01MH089722-01A1 from National Institute Of Mental Health
Abstract: There are 2.5 million children living the HIV/AIDS worldwide. Most live in resource- limited settings. Treatment guidelines for children are often based on findings in adults and seldom assembled from studies employing a randomized design. This rationale led the NIH to initiate the PREDICT study underway in Thailand and Cambodia. PREDICT uses a randomized design to determine the optimal timing of antiretroviral initiation in children. International guidelines for ART initiation in children older than 12 months continue to recommend deferring therapy until symptomatic disease or immune compromise occurs, despite studies in younger infants (CHER trial) identifying a benefit for early treatment. Treatment outcomes for older children are needed and neurodevelopmental outcomes could critically inform guidelines. This proposal will add robust neurodevelopmental and imaging outcomes to PREDICT. This work will extend our current limited evaluation of neurodevelopmental outcomes to determine if differences in long-term neuropsychological and neurological outcomes exist in relation to deferring antiretroviral therapy. We will also enroll needed HIV-negative comparative groups of HIV-exposed and unexposed children. Since microencephaly is a common manifestation of HIV in children, volumetric analyses may be most informative. Should the primary findings from PREDICT fail to identify differences by randomized group (immediate compared to deferred therapy), findings from the proposed work may have an enormous impact by informing treatment guidelines worldwide. HIV treatment guidelines for children are based on incomplete evidence. Neurodevelopmental outcomes may critically inform these guidelines. The proposed work will determine the brain impact of deferring antiretroviral therapy until there is immunosuppression, as currently recommended by WHO guidelines. Our findings may have an enormous impact on worldwide treatment recommendations
Keywords: 0-11 years old; 21+ years old; AIDS Virus; AIDS/HIV; AIDS/HIV problem; Accounting; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Acquired brain injury; Address; Adult; Age; Age-Months; Anisotropy; Anti-Retroviral Agents; Antiretroviral Agents; Arm; Body measure procedure; Body of the Corpus Callosum; Brain; Brain Injuries; Brain imaging; Cambodia; Child; Child Behavior Checklist; Child Youth; Childhood Injury; Children (0-21); Cognitive; Control Groups; Corpus Callosum; Corpus Callosums; Data; Diffusion MRI; Diffusion Magnetic Resonance Imaging; Diffusion Weighted MRI; Disease; Disorder; Early treatment; Encephalon; Encephalons; Enrollment; Ensure; Evaluation; Funding; Generalized Growth; Growth; Guidelines; HIV; HIV/AIDS; HIV/AIDS problem; HOSP; HTLV-III; Hospitalization; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Human, Adult; Human, Child; Image; Immune; Immunosuppression Effect; Immunosuppressions (Physiology); Immunosuppressive Effect; Infant; International; Kampuchea; Khmer Republic; LAV-HTLV-III; Life; Longitudinal Studies; Lymphadenopathy-Associated Virus; Measures; Measures, Body; Microcephaly; Multimodal Imaging; Multimodality; NIH; National Institutes of Health; National Institutes of Health (U.S.); Natural immunosuppression; Nervous System, Brain; Neural Development; Neurologic; Neurologic outcome; Neurological; Neurological outcome; Neuropsychologic Tests; Neuropsychological Tests; Outcome; Principal Investigator; Programs (PT); Programs [Publication Type]; Randomized; Recommendation; Research Design; Research Resources; Resources; Societies; Speed; Speed (motion); Structure of body of corpus callosum; Study Type; Thailand; Time; Tissue Growth; Toxic effect; Toxicities; Treatment outcome; United States National Institutes of Health; Upper arm; Virus-HIV; Work; adult human (21+); anti-retroviral; antiretroviral; antiretroviral therapy; base; brain damage; brain lesion (from injury); brain size; brain visualization; brain volume; children; comparative; corpus callosum body; design; designing; diffusion tensor imaging; disease/disorder; enroll; frontal cortex; frontal lobe; imaging; immunosuppression; injury in children; long-term study; member; micrencephaly; microencephaly; morphometry; neurodevelopment; neuropsychological; ontogeny; primary outcome; processing speed; programs; public health relevance; randomisation; randomization; randomly assigned; study design; substantia alba; success; treatment program; trend; white matter; youngster
Relevance: Relevance: HIV treatment guidelines for children are based on incomplete evidence. Neurodevelopmental outcomes may critically inform these guidelines. The proposed work will determine the brain impact of deferring antiretroviral therapy until there is immunosuppression, as currently recommended by WHO guidelines. Our findings may have an enormous impact on worldwide treatment recommendations
Project start date: 2010-05-18
Project end date: 2013-03-31
Budget start date: 18-MAY-2010
Budget end date: 31-MAR-2011
PFA/PA: PA-07-070
1R01MH089722-01A1 (2010): $597012
DEMENTIA IN HIV PATIENTS OVER 60 YEARS OF AGE
Victor Valcour, Assistant Professor
University Of California San Francisco, 3333 California St., Ste 315, San Francisco, Ca 94143-0962
Grant 5K23AG032872-03 from National Institute On Aging
Abstract: The number of HIV patients who are over 60 years of age is rapidly increasing in the US and will likely represent a geriatric population for which there are limited scientific data to direct care in the next decade. These substantial HIV demographic changes, largely driven by long-term survival due to potent treatment; will require new guidelines to direct optimal care and greater emphasis on well-designed hypothesis-driven research initiatives to direct these guidelines. This application aims to determine the relative impact of increased cerebrovascular disease (CVD) risk factors on cognition in a population of HIV patients over 60 years of age with a long-term goal of determining the extent to which CVD and Alzheimer´s disease (AD) interact to impact cognitive health in aged HIV patients. Our hypotheses are driven by previous work identifying an age-associated increased risk for dementia in HIV, an increased risk for dementia associated with diabetes among older HIV patients, and preliminary support that CVD risk factors may impact white matter integrity and cognition in aged HIV patients. When considered in the context of recent discoveries describing abnormal accumulation of amyloid in HIV and the recognized age-associated risk of AD and CVD, there is compelling evidence that interactions among AD, CVD and HIV may accelerate cognitive abnormalities in the oldest HIV patients. Specifically, this application will add structural quantitative MRI and Diffusion Tensor Imaging (DTI) at high field (4.0 Tesla) to a longitudinal cohort of fifty HIV patients over 60 years of age to determine the relative impact of CVD risk factors on changes in white matter integrity and to determine the extent to which changes in white matter integrity impact cognitive performance. While completing this highly relevant research, the candidate will strengthen his clinical skills in the differential diagnosis of cognitive disorders of aging with particular emphasis on potential interactions with HIV and learn the neuroimaging techniques required for quantitative structural MRI analyses and DTI. A combination of clinical mentor (Bruce Miller MD, primary), neuroimaging mentor (Michael Weiner MD, secondary), and the remarkable environment of the Memory and Aging Center at UCSF are highly likely to result in transition to independent researcher
Keywords: AIDS Virus; AIDS neuropathy; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Age; Age-Years; Aged 65 and Over; Aging; Alzheimer; Alzheimer disease; Alzheimer sclerosis; Alzheimer syndrome; Alzheimer`s; Alzheimer`s Disease; Alzheimer`s disease risk; Alzheimers Dementia; Alzheimers disease; Amentia; Amyloid; Amyloid Substance; Anisotropy; Autopsy; Blood Pressure, High; Body Tissues; Brain; Brain Vascular Disorders; CD4 Lymphocyte Count; CD4+ Cell Counts; CD4+ Counts; California; Caring; Cerebrovascular Disease; Cerebrovascular Disorders; Clinical; Clinical Skills; Cognition; Cognition Disorders; Cognitive; Collaborations; Data; Dementia; Dementia, Alzheimer Type; Dementia, Primary Senile Degenerative; Dementia, Senile; Deterioration; Diabetes Mellitus; Differential Diagnosis; Diffusion MRI; Diffusion Magnetic Resonance Imaging; Diffusion Weighted MRI; Elderly; Elderly, over 65; Encephalon; Encephalons; Enrollment; Environment; Equipment and supply inventories; Functional impairment; Future; Goals; Grant; Guidelines; HIV; HTLV-III; Health; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Hypercholesteremia; Hypertension; Impairment; Intracranial Vascular Disorders; Inventory; Investigators; LAV-HTLV-III; Learning; Letters; Lymphadenopathy-Associated Virus; MR Imaging; MR Tomography; MRI; Magnetic Resonance Imaging; Magnetic Resonance Imaging Scan; Measures; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; Memory; Mentors; Methods and Techniques; Methods, Other; NMR Imaging; NMR Tomography; Nervous System, Brain; Neurologic; Neurological; Neuropsychologic Tests; Neuropsychological Tests; Nuclear Magnetic Resonance Imaging; Participant; Patients; Performance; Population; Primary Senile Degenerative Dementia; Programs (PT); Programs [Publication Type]; Relative; Relative (related person); Research; Research Personnel; Researchers; Risk; Risk Factors; Senescence; Smoking; Speed; Speed (motion); T4 Lymphocyte Count; Techniques; Tissues; Vascular Diseases, Intracranial; Vascular Hypertensive Disease; Vascular Hypertensive Disorder; Virus-HIV; White Matter Disease; Work; Zeugmatography; advanced age; aged; cognitive disease; cognitive disorder; cohort; dementia of the Alzheimer type; design; designing; diabetes; diffusion tensor imaging; disease risk; disorder risk; elders; enroll; executive control; executive function; functional disability; geriatric; hypercholesterolemia; hyperpiesia; hyperpiesis; hypertensive disease; late life; later life; necropsy; neuroAIDS; neuroimaging; older adult; older person; postmortem; primary degenerative dementia; programs; senescent; senile dementia of the Alzheimer type; senior citizen; substantia alba; white matter; white matter injury
Project start date: 2008-09-30
Project end date: 2011-07-31
Budget start date: 1-AUG-2010
Budget end date: 31-JUL-2011
PFA/PA: RFA-AG-08-006
5K23AG032872-03 (2010): $214800
5K23AG032872-02 (2009): $214480
1K23AG032872-01 (2008): $214100
PERIPHERAL RESERVOIR OF HIV DNA IN MONOCYTES PIVOTAL TO COGNITION IN HIV
Victor Valcour, Assistant Professor
University Of California San Francisco, 3333 California St., Ste 315, San Francisco, Ca 94143-0962
Grant 5R01NS061696-03 from National Institute Of Neurological Disorders And Stroke
Abstract: Recent data from our program demonstrate that the level of HIV DNA within peripheral blood mononuclear cells (PBMC HIV DNA) is a strong marker of cognitive impairment in patients who are naive to HAART, patients on chronic HAART, and among patients with undetectable plasma HIV RNA. Based on preliminary data, PBMC HIV DNA likely represents the degree of HIV infection in circulating monocytes rather than lymphocytes. Since activated cells of the monocyte/macrophage lineage play a pivotal role in the pathogenesis of HIV-associated Dementia (HAD), HIV DNA may be an important neuropathogenic marker. New data presented in this application reveal that pre-HAART HIV DNA level predicts 12-month post-HAART cognitive function. We also present evidence that HIV DNA may increase monocyte chemotaxis by elevating MCP-1 secretion from monocytes, a finding that would be expected to increase transmigration of monocytes to the brain. The potential significance of these findings becomes more apparent in the context of incomplete cognitive recovery after HAART. Incomplete cognitive recovery could be an active or passive (permanent brain damage) process. A major gap in our current knowledge relates to a lack of biological marker of this incomplete recovery. Developing our hypotheses is likely to advance this area of science and bridge this gap in our knowledge-base. We propose to define the long-term dynamic relationship between the inability of HAART to eradicate HIV DNA in the peripheral monocyte reservoir and cognitive performance among patients initiating HAART for the first time in Bangkok, Thailand. We will define the clinical correlate with neuropsychological testing and evaluate mechanisms by determining the extent to which HIV DNA contributes to monocyte activation in peripheral blood and glial activation by MR spectroscopy and by CSF markers of immune activation while ensuring that the primary effects of HIV DNA are not due to increased HIV RNA in CSF. PUBLIC HEALTH RELEVANCE This proposal will study whether high levels of HIV infected monocytes (a type of cell in the bloodstream) that persist in HIV-infected individuals who receive good antiretroviral therapy against HIV explain why dementia does not completely resolve following such therapy. Understanding why this happens will allow us to find better ways to prevent or treat this devastating complication of HIV
Keywords: 2-Amino-6-(1, 2, 3-trihydroxypropyl)-4(3H)-pteridi; AIDS Dementia; AIDS Dementia Complex; AIDS Virus; AIDS with dementia; AIDS-related dementia; Acquired Immune Deficiency Syndrome Virus; Acquired Immune Deficiency Syndrome related dementia; Acquired Immunodeficiency Syndrome Virus; Acquired brain injury; Aging; Amentia; Antiretroviral Therapy, Highly Active; Area; B cell differentiation factor; B cell stimulating factor 2; B-Cell Differentiation Factor-2; B-Cell Stimulatory Factor-2; BCDF; BSF-2; BSF2; BSF2 (B cell stimulating factor 2); Biologic Marker; Biological Markers; Blood Circulation; Blood Plasma; Blood monocyte; Bloodstream; Brain; Brain Injuries; CCL2; CCL2 gene; CD14; CD14 gene; Cells; Characteristics; Chemotaxis; Chronic; Circulation; Clinical; Cognition; Cognition Disorders; Cognitive; Cognitive Disturbance; Cognitive Impairment; Cognitive decline; Cognitive function abnormal; Complication; Consensus; Country; Creatine; DNA; Data; Dementia; Dementia Complex, AIDS-Related; Dementia Complex, Acquired Immune Deficiency Syndrome; Dementia Due to HIV Disease; Dementia associated with AIDS; Dementia in human immunodeficiency virus (HIV) disease; Deoxyribonucleic Acid; Diagnosis; Differentiation Factor, B-Cell; Disease; Disorder; Disturbance in cognition; Drug usage; Encephalon; Encephalons; Encephalopathies; Enrollment; Ensure; GDCF-2; GDCF-2 HC11; Gene Products, RNA; Glycine, N-(aminoiminomethyl)-N-methyl-; HAART; HC11; HCV infection; HIV; HIV Dementia; HIV Infections; HIV associated dementia; HIV-1 associated dementia; HIV-1 dementia; HIV-Associated Cognitive Motor Complex; HIV-related dementia; HPGF; HTLV-III; HTLV-III Infections; HTLV-III-LAV Infections; Hawaii; Hepatitis C; Hepatitis C virus infection; Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted; Hepatocyte-Stimulating Factor; Highly Active Antiretroviral Therapy; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Hybridoma Growth Factor; IFN-beta 2; IFNB2; IL-6; IL6 Protein; INFLM; Impaired cognition; Individual; Infection; Inflammation; Interleukin 6 (Interferon, Beta 2); Interleukin-6; International; Knowledge; LAV-HTLV-III; Lymphadenopathy-Associated Virus; Lymphocyte; Lymphocytic; MCAF; MCP-1; MCP1; MGC9434; MGI-2; MR Spectroscopy; MRS; MRSI; Magnetic Resonance Spectroscopy; Marrow monocyte; Measures; Metric; Molecular Marker; Myeloid Differentiation-Inducing Protein; NANBH; Neopterin; Nervous System, Brain; Neuronal Dysfunction; Neuropsychologic Tests; Neuropsychological Tests; PBMC; PT-NANBH; Parenterally-Transmitted Non-A, Non-B Hepatitis; Pathogenesis; Patients; Pattern; Performance; Peripheral; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Plasmacytoma Growth Factor; Play; Principal Investigator; Process; Programs (PT); Programs [Publication Type]; Public Health; Publishing; RNA; RNA, Non-Polyadenylated; Recovery; Research; Research Resources; Resources; Reticuloendothelial System, Serum, Plasma; Ribonucleic Acid; Role; SCYA2; SIV; SMC-CF; Science; Senescence; Serum, Plasma; Signature Molecule; Simian Immunodeficiency Viruses; T-Lymphotropic Virus Type III Infections, Human; Testing; Thailand; Time; Toxicology; Urinary System, Urine; Urine; Viral; Virus-HIV; Work; anti-retroviral therapy, highly active; antiretroviral therapy; base; biomarker; brain damage; brain lesion (from injury); brain tissue; case-based; cell type; cognitive disease; cognitive disorder; cognitive dysfunction; cognitive function; cognitive loss; cognitive recovery; cognitively impaired; cohort; conference; disease/disorder; drug use; enroll; hepatitis non A non B; hepatitis nonA nonB; immune activation; interferon beta 2; knowledge base; lymph cell; macrophage; mild cognitive disorder; mild cognitive impairment; mild neurocognitive disorder; monocyte; myoinositol; non A non B hepatitis; non A, non B hepatitis; non-A non-B hepatitis; non-A, non-B hepatitis; peripheral blood; prevent; preventing; programs; public health medicine (field); public health relevance; senescent; social role; substantia alba; symposium; trafficking; white matter
Project start date: 2008-08-15
Project end date: 2013-07-31
Budget start date: 1-AUG-2010
Budget end date: 31-JUL-2011
PFA/PA: PA-07-070
5R01NS061696-03 (2010): $605317
7R01NS061696-02 (2009): $658773
1R01NS061696-01A1 (2008): $679088
CENTRAL NERVOUS SYSTEM EFFECTS IN ACUTE HIV SEROCONVERSION
Victor Valcour, Assistant Professor
University Of California San Francisco, 3333 California St., Ste 315, San Francisco, Ca 94143-0962
Grant 5R21MH086341-02 from National Institute Of Mental Health
Abstract: It is increasingly evident that the events which occur during acute HIV infection have a lasting impact on HIV disease course. Brain injury may occur in this very early stage, a factor that is sometime clinically evident with neurological manifestations of disease and is thought to have long-standing consequences. To date, our understanding of these earliest CNS effects are limited since capturing clinical data in the weeks following infection requires extensive resources and since such individuals seldom succumb to autopsy. Information relating to the first few weeks following infection is particularly lacking as few centers are able to identify infection in this very early phase. Intensive neurological and psychological characterization of acute infection would greatly advance our understanding of brain injury in HIV. Our collaborative organization in Bangkok, Thailand, known as the Southeast Asia Research Collaboration with Hawaii (SEARCH), will launch a US Department of Defense-funded protocol in the fall of 2008 to capture up to thirty acute HIV-infected cases in 2 years. All individuals will have been infected within the three weeks prior to enrollment (HIV antibody negative, nucleic acid positive). Broadly focused on vaccine development goals to characterize immunological changes associated with acute infection and the potential impact of mega- HAART in early infection, this cohort provides an unmatched opportunity to assess the neurological manifestations of HIV during acute HIV infection in a predominantly non-subtype B epidemic. In this application, we propose to acquire MR Spectroscopy, neurological assessments, neuropsychological testing, psychiatric characterization and cerebrospinal fluid (CSF) in twenty such cases at baseline and longitudinally for 96 weeks. Our primary goal is to quantify brain injury and CNS inflammation during this early phase of infection and to correlate these parameters to intracellular HIV DNA and systemic immune status during the acute HIV infection period. We will also store peripheral blood mononuclear cells (PBMC) and CSF for future collaborative studies with particular interest in viral sequencing in blood and CSF. This project will aid in clarifying the earliest events during HIV infection with regard to brain injury to determine the extent to which the brain is affected immediately after infection
Keywords: 2-Amino-6-(1, 2, 3-trihydroxypropyl)-4(3H)-pteridi; 2-Hydroxy-N, N, N-trimethylethanaminium; AIDS Antibodies; AIDS Seroconversion; AIDS Seropositivity; AIDS Virus; AIDS neuropathy; Acquired Immune Deficiency Syndrome Virus; Acquired Immunodeficiency Syndrome Virus; Acquired brain injury; Acute; Affect; Anti-HIV Positivity; Antiretroviral Therapy, Highly Active; Area; Arm; Armed Forces Personnel; Asia, Southeastern; Assay; Attenuated; Autopsy; B cell differentiation factor; B cell stimulating factor 2; B-Cell Differentiation Factor-2; B-Cell Stimulatory Factor-2; BCDF; BSF-2; BSF2; BSF2 (B cell stimulating factor 2); Bioassay; Biologic Assays; Biological Assay; Blood; Blood Plasma; Brain; Brain Injuries; Brain region; CCL2; CCL2 gene; Central Nervous System; Cerebrospinal Fluid; Choline; Clinical; Clinical Data; Collaborations; DNA; DOD; Data; Deoxyribonucleic Acid; Department of Defense; Differentiation Factor, B-Cell; Disease; Disorder; Encephalon; Encephalons; Enrollment; Environment; Enzyme Immunoassay; Epidemic; Ethanaminium, 2-hydroxy-N, N, N-trimethyl-; Evaluation; Event; Funding; Future; GDCF-2; GDCF-2 HC11; Generations; Goals; HAART; HC11; HIV; HIV Antibodies; HIV Antibody Positivity; HIV Infections; HIV Positive; HIV Positivity; HIV Seroconversion; HIV Seropositivity; HIV-Associated Antibodies; HPGF; HTLV-III; HTLV-III Antibodies; HTLV-III Infections; HTLV-III Seroconversion; HTLV-III Seropositivity; HTLV-III-LAV Antibodies; HTLV-III-LAV Infections; Hawaii; Hepatocyte-Stimulating Factor; Highly Active Antiretroviral Therapy; Human Immunodeficiency Viruses; Human T-Cell Leukemia Virus Type III; Human T-Cell Lymphotropic Virus Type III; Human T-Lymphotropic Virus Type III; Hybridoma Growth Factor; IFN-beta 2; IFNB2; IL-6; IL6 Protein; INFLM; Image; Immune; Immune Markers; Immunologic Markers; Immunologic, Enzyme Linked Immunoassay; Individual; Infection; Infectious Diseases / Laboratory; Infectious Diseases Research; Inflammation; Injury; Interleukin 6 (Interferon, Beta 2); Interleukin-6; International; Intervention; Intervention Strategies; LAV Antibodies; LAV-HTLV-III; Laboratories; Letters; Lumbar Puncture; Lymphadenopathy-Associated Antibodies; Lymphadenopathy-Associated Virus; MCAF; MCP-1; MCP1; MGC9434; MGI-2; MR Imaging; MR Spectroscopy; MR Tomography; MRI; MRS; MRSI; MT-bound tau; Magnetic Resonance Imaging; Magnetic Resonance Imaging Scan; Magnetic Resonance Spectroscopy; Medical; Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance; Military; Military Personnel; Mucosa; Mucosal Tissue; Mucous Membrane; Myeloid Differentiation-Inducing Protein; N-acetyl aspartate; N-acetyl-L-aspartate; N-acetylaspartate; NAT; NMR Imaging; NMR Tomography; Neopterin; Nervous System, Brain; Nervous System, CNS; Neuraxis; Neurologic; Neurologic Manifestations; Neurologic Signs and Symptoms; Neurological; Neurological Manifestations; Neuronal Injury; Neuropsychologic Tests; Neuropsychological Tests; Nuclear Magnetic Resonance Imaging; Nucleic Acid Amplification Tests; Nucleic Acid Testing; Nucleic Acids; Operation; Operative Procedures; Operative Surgical Procedures; PBMC; Peripheral; Peripheral Blood Mononuclear Cell; Phase; Plasma; Plasmacytoma Growth Factor; Programs (PT); Programs [Publication Type]; Protocol; Protocols documentation; Research; Research Institute; Research Resources; Resources; Reticuloendothelial System, Blood; Reticuloendothelial System, Serum, Plasma; Retrovirology; SCYA2; SMC-CF; Science; Serum, Plasma; Site; Southeast Asia; Southeastern Asia; Spinal Puncture; Staging; Surgical; Surgical Interventions; Surgical Procedure; T-Lymphotropic Virus Type III Antibodies, Human; T-Lymphotropic Virus Type III Infections, Human; Thailand; Time; Upper arm; Viral; Virus-HIV; Work; Zeugmatography; anti-retroviral therapy, highly active; antibody positive AIDS test; antigen positive AIDS test; base; brain damage; brain lesion (from injury); cohort; cost; disease/disorder; enroll; falls; imaging; interest; interferon beta 2; interventional strategy; microtubule associated protein tau; microtubule bound tau; microtubule-associated protein tau; microtubule-bound tau; myoinositol; necropsy; neural manifestation; neuroAIDS; neuron injury; neuropsychological; postmortem; programs; psychologic; psychological; public health relevance; seropositive (AIDS test); spinal fluid; surgery; tau; tau Proteins; tau factor; vaccine development
Relevance: . Project Relevance: This project will aid in clarifying the earliest events during HIV infection with regard to brain injury to determine the extent to which the brain is affected immediately after infection.
Project start date: 2009-07-01
Project end date: 2011-05-31
Budget start date: 1-JUN-2010
Budget end date: 31-MAY-2011
PFA/PA: PA-06-181
5R21MH086341-02 (2010): $174478
1R21MH086341-01 (2009): $193020